GET THE APP

Serum SH3BP5-specific Antibody Level is a Biomarker of Atherosclerosis | Abstract
Immunome Research

Immunome Research
Open Access

ISSN: 1745-7580

Abstract

Serum SH3BP5-specific Antibody Level is a Biomarker of Atherosclerosis

Hiwasa T, Tomiyoshi G, Nakamura R, Shinmen N, Kuroda H, Kunimatsu M, Mine S, Machida T, Sato E, Takemoto M, Hattori A, Kobayashi K, Kawamura H, Ishibashi R, Yokote K, Kitamura K, Ohno M, Chen PM, Nishi E, Ono K, Kimura T, Takizawa H, Kashiwado K, Kamitsukasa I, Wada T, Aotsuka A, Sunami K, Kobayashi E, Yoshida Y, Matsutani T, Iwadate Y, Mori M, Uzawa A, Muto M, Sugimoto K, Kuwabara S, Iwata Y, Kobayashi Y, Terada J, Matsumura T, Sakao S, Tatsumi K, Ito M, Shimada H, Zhang XM, Kimura R, Wang H, Iwase K, Ashino H, Taira A, Arita E, Goto K and Doi H

Abstract Background: The discovery and development of novel biomarkers that could facilitate early diagnosis and thus prevent the progression of atherosclerosis-related diabetes mellitus (DM), cerebral infarction (CI), and cardiovascular disease (CVD) has garnered much research interest. Notably, recent reports have described a number of highly sensitive antibody markers. In this study, we aimed to identify additional antibody markers that would facilitate screening. Methods: The amplified luminescent proximity homogeneous assay (AlphaLISA) method, which incorporates glutathione- or streptavidin-donor beads and anti-human-IgG-acceptor beads, was used to evaluate serum antibody levels in serum samples. The protein array method was used for the initial screening, and peptide arrays were used to identify epitope sites. Results: The protein array identified SH3 domain-binding protein 5 (SH3BP5) as a target antigen of serum IgG antibodies in the sera of patients with atherosclerosis. We prepared recombinant glutathione S-transferase (GST)- fused SH3BP5 protein. Peptide arrays revealed that the epitope site recognized by serum antibodies is located within amino acids 161–174 of SH3BP5. AlphaLISA revealed significantly higher serum antibody levels against both the SH3BP5 protein and peptide in patients with DM, acute-phase CI, transient ischemic attack, CVD or chronic kidney disease (CKD), than in healthy donors. Furthermore, areas under the receiver operating characteristic curves of these antibodies were higher in patients with CKD and DM than in other patients. Spearman correlation analysis revealed associations between the serum antibody levels against SH3BP5 peptide and artery stenosis, hypertension, and smoking. Conclusions: The serum anti-SH3BP5 antibody marker appears to be useful for estimating the progress of atherosclerosis and may discriminate atherosclerosis associated with hypertension and/or habitual smoking.

Top